Wire open Last filed CagriSema bone density data at ObesityWeek point to a calcitonin receptor role RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

RoutineTRLNews

CagriSema bone density data at ObesityWeek point to a calcitonin receptor role

Novo Nordisk showed rat, volunteer and post hoc REDEFINE 1 data suggesting amylin and calcitonin receptor drugs may limit bone loss during weight loss. The company calls the work hypothesis generating, and fractures were not studied.

PLAINSBORO, NJ

43%Higher femur trabecular bone volume with cagrilintide than weight matched controls in a rat menopause model
  1. What's newNovo Nordisk presented rat, volunteer and post hoc REDEFINE 1 data at ObesityWeek 2026 suggesting that activating amylin and calcitonin receptors may limit bone loss during weight loss.
  2. Why it mattersLarge weight loss can thin bone and raise fracture risk, a concern for older women, and CagriSema is under FDA review for weight management.
  3. What's nextNovo says longer clinical studies are needed to test bone outcomes, and an FDA decision on CagriSema is expected in the fourth quarter of 2026.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. REG · 17 Nov 2026The EMA's CHMP adopted a DHPC advising women on oral contraceptives who use Mounjaro to add a barrier method for four weeks after starting and after each dose increase, or switch to a non oral method.
  2. TRL · 16 Nov 2026In the Phase 3 LUCIDITY trial, once daily avexitide cut weekly level 2 and 3 hypoglycemia events after gastric bypass to 0.55 versus 1.24 on placebo, a rate ratio of 0.45.
  3. REG · 16 Nov 2026The FDA required makers of all GLP 1 receptor agonists to add a possible higher risk of NAION, a rare optic nerve stroke, to the Warnings and Precautions section of their labels.
  4. TRL · 16 Nov 2026JAMA published the Phase 3 GEMINI 1 trial of once weekly ribupatide in 567 Chinese adults without diabetes, showing 10.7% to 17.7% weight loss at 48 weeks across three doses.
  5. IND · 16 Nov 2026Blackstone Life Sciences agreed to fund up to 1.5 billion dollars of development costs for Pfizer's monthly GLP 1 peptide berobenatide through 2028, in return for milestone payments.

By the numbers

The one figure each story turns on.

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Desk fronts

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator18
  • Journal12
  • Company release26
  • Conference10
  • Our newsroom35